

Annual Meeting of Shareholders

April 23, 2009 Atlanta, Georgia



Announcements and Forward-Looking Statement

Matt Lepore
Chief Counsel and Corporate Secretary

Order of Business

- I. Chairman's Welcome and Report
- **II.** Call to Order for Business Meeting
- III. Declaration of a Quorum
- **IV.** Voting Items
- V. Final Voting and Closing of Polls
- VI. Preliminary Results of Voting
- VII. Questions and Answers
- VIII. Adjournment





Announcements and Forward-Looking Statement

Matt Lepore
Chief Counsel and Corporate Secretary



Chairman's Welcome and Report

Achieving Our Stated Goals

Overcome patent expirations, keep revenues steady



Improve R&D productivity



► Manage costs



▶ Strengthen our culture









Asking the Tough Questions



How is Pfizer doing in this time of extreme economic turmoil?

Pfizer: Strong Finances and Operations

Strong Financially

- Strong balance sheet
- Excellent liquidity, cash flow, credit ratings
- Conservative investment practices

Solid Operational Performance

▶ On track for 2009 goals







Why did Pfizer cut its dividend?





Why is Pfizer buying Wyeth?

Extends Global Healthcare Leadership

Drives Improved
Performance Through
Unique, Flexible Business
Model

Strengthens Platforms for Improved, Consistent and Stable Earnings Growth

Enhances Ability to Meet
Unmet Needs
of Patients, Physicians and
Other Customers

Extends Global Healthcare Leadership

Drives Improved
Performance Through
Unique, Flexible Business
Model

Strengthens P. Improved, Cons. Stable Earnings

- In developed and developing markets
- Primary and Specialty Care
- Vaccines, Biologics and Small Molecules
- Animal Health, Consumer Health, Nutritionals

Extends Global Healthcare Leadership

Drives Improved
Performance Through
Unique. Flexible Business

- Focused, agile business units
- Strong resources, scale of global enterprise
- Rapid and effective integration of Wyeth

ی to Meet veeds hysicians and Customers

Extends Global Lead

- Definitively addresses revenue loss from Lipitor loss of exclusivity
- Broad, diversified portfolio of growth drivers
- New therapies: largest selling vaccine, best selling biologic medicine

Strengthens Platforms for Improved, Consistent and Stable Earnings Growth

Unmet Needs
of Patients, Physicians and
Other Customers

- Augments in-line and pipeline portfolio in critical disease areas
- Enhance our scientific and manufacturing capabilities
- Opens doors of opportunity for talented people
- Broad diversity of product lines; stable of fast growing medicines

Improved, Consistent and Stable Earnings Growth

Improved
Through
Business

....y to Weet

Unmet Needs of Patients, Physicians and Other Customers

Extends Global Healthcare Leadership

Drives Improved
Performance Through
Unique, Flexible Business
Model

Strengthens Platforms for Improved, Consistent and Stable Earnings Growth

Enhances Ability to Meet
Unmet Needs
of Patients, Physicians and
Other Customers



What has happened to Pfizer's share price since the Wyeth announcement?





What's happening with the pipeline?

Driving R&D Productivity

- Two new high-potential products in Phase 3
 - –JAK-3 inhibitor: a new approach to Rheumatoid Arthritis
 - -Tanezumab: a new approach to knee pain



A Broad, Diverse, High-Value Pipeline

100 Programs in Pipeline

Discovery Projects

Phase 1
40

Phase 2
33

Phase 3
25

Phase 3
100

Total 100

12 of these in high-priority disease areas, including diabetes, cancer, Alzheimer's disease and others



Poised to Make Progress on All Fronts

PharmaTherapeutics Research Group

BioTherapeutics Research Group

Business Units

Development/

Medical

Sales & Marketing



R&D Is Focused on Critical Diseases


Alzheimer's




Arthritis




Cancer




Diabetes



Expands High Priority Disease Areas and Enhances Biologics Capabilities



Vaccines



Infectious Diseases



Biotherapeutics











What was your compensation in 2008, and why was it set at that level?





Your Interests Are Our Interests



Why should you invest in Pfizer?

Pfizer: Within Our Reach

- Market leadership in key regions... and in medicines and animal health
- Leadership in primary and specialty care
- ► A dynamic oncology business
- **► Highly innovative** vaccines business
- ► A leading biotherapeutics business
- ► A broadly based **Established Products** business
- Solid positions in <u>diverse businesses</u>
- A strong late stage pipeline and <u>leading edge</u> scientific collaborations









Call to Order For Business Meeting

- I. Chairman's Welcome and Report
- II. Call to Order for Business Meeting
- **III.** Declaration of a Quorum
- IV. Voting Items
- V. Final Voting and Closing of Polls
- VI. Preliminary Results of Voting
- VII. Questions and Answers
- VIII. Adjournment



- I. Chairman's Welcome and Report
- II. Call to Order for Business Meeting
- **III.** Declaration of a Quorum
- IV. Voting Items
- V. Final Voting and Closing of Polls
- VI. Preliminary Results of Voting
- VII. Questions and Answers
- VIII. Adjournment



- I. Chairman's Welcome and Report
- II. Call to Order for Business Meeting
- III. Declaration of a Quorum
- IV. Voting Items
- V. Final Voting and Closing of Polls
- VI. Preliminary Results of Voting
- VII. Questions and Answers
- VIII. Adjournment





A Quorum is Present

- I. Chairman's Welcome and Report
- II. Call to Order for Business Meeting
- III. Declaration of a Quorum
- IV. Voting Items
- V. Final Voting and Closing of Polls
- VI. Preliminary Results of Voting
- VII. Questions and Answers
- VIII. Adjournment



To Ensure Fair Play for All Shareholders

- ► Please hold questions or comments about an Item until after it has been introduced
- Please focus only on the Item being discussed
- **▶** Please wait for a microphone
- When recognized, please state your name and shareholder status
- **▶** Please respect time limits





Voting – Or Changing Your Vote



The Polls Are Open

- I. Chairman's Welcome and Report
- **II.** Call to Order for Business Meeting
- **III.** Declaration of a Quorum
- IV. Voting Items
- V. Final Voting and Closing of Polls
- VI. Preliminary Results of Voting
- VII. Questions and Answers
- VIII. Adjournment

Item 1:

Election of Directors








Dr. Dennis A. Ausiello

Chief of Medicine, Massachusetts General Hospital





Dr. Michael S. Brown

Distinguished Chair, Biomedical Sciences, University of Texas / Southwestern Medical Center






M. Anthony Burns

Chairman Emeritus, Ryder System, Inc






Robert N. Burt

Retired Chairman and CEO, FMC Corporation





W. Don Cornwell

Chairman and CEO,
Granite Broadcasting Corporation





William H. Gray, III

Chairman, Amani Group






Constance J. Horner

Former Assistant to the President of the United States, and Director of Presidential Personnel






James M. Kilts

Founding Partner of Centerview Partners






George A. Lorch

Chairman Emeritus, Armstrong Holdings, Inc





Dr. Dana G. Mead

Chairman, MIT Corporation





Suzanne Nora Johnson

Former Vice Chairman,
The Goldman Sachs Group, Incorporated





Stephen W. Sanger

Former Chairman, General Mills





William C. Steere, Jr.,

Chairman of the Board, Emeritus, Pfizer Inc


- I. Chairman's Welcome and Report
- **II.** Call to Order for Business Meeting
- **III.** Declaration of a Quorum
- IV. Voting Items
- V. Final Voting and Closing of Polls
- VI. Preliminary Results of Voting
- VII. Questions and Answers
- VIII. Adjournment

Item 1:

Election of Directors







William R. Howell

Chairman Emeritus, J.C. Penney Company

- I. Chairman's Welcome and Report
- **II.** Call to Order for Business Meeting
- III. Declaration of a Quorum
- IV. Voting Items
- V. Final Voting and Closing of Polls
- VI. Preliminary Results of Voting
- VII. Questions and Answers
- VIII. Adjournment

Item 1:

Election of Directors



- I. Chairman's Welcome and Report
- **II.** Call to Order for Business Meeting
- III. Declaration of a Quorum
- IV. Voting Items
- V. Final Voting and Closing of Polls
- VI. Preliminary Results of Voting
- VII. Questions and Answers
- VIII. Adjournment

Item 2:

Ratifying Selection of KPMG



- I. Chairman's Welcome and Report
- **II.** Call to Order for Business Meeting
- III. Declaration of a Quorum
- IV. Voting Items
- V. Final Voting and Closing of Polls
- VI. Preliminary Results of Voting
- VII. Questions and Answers
- VIII. Adjournment

Item 3:

Shareholder
Proposal
on 2004 Pfizer
Stock Plan



- I. Chairman's Welcome and Report
- **II.** Call to Order for Business Meeting
- III. Declaration of a Quorum
- IV. Voting Items
- V. Final Voting and Closing of Polls
- VI. Preliminary Results of Voting
- VII. Questions and Answers
- VIII. Adjournment

Item 4:

Shareholder
Proposal
On Stock
Options



- I. Chairman's Welcome and Report
- **II.** Call to Order for Business Meeting
- III. Declaration of a Quorum
- IV. Voting Items
- V. Final Voting and Closing of Polls
- VI. Preliminary Results of Voting
- VII. Questions and Answers
- VIII. Adjournment

Item 5:

Shareholder
Proposal
On Advisory
Vote On
Compensation



- I. Chairman's Welcome and Report
- **II.** Call to Order for Business Meeting
- III. Declaration of a Quorum
- IV. Voting Items
- V. Final Voting and Closing of Polls
- VI. Preliminary Results of Voting
- VII. Questions and Answers
- VIII. Adjournment

Item 6:

Shareholder Proposal On Cumulative Voting



- I. Chairman's Welcome and Report
- **II.** Call to Order for Business Meeting
- III. Declaration of a Quorum
- IV. Voting Items
- V. Final Voting and Closing of Polls
- VI. Preliminary Results of Voting
- VII. Questions and Answers
- VIII. Adjournment

Item 7:

Shareholder Proposal On Special Shareholder Meetings



- I. Chairman's Welcome and Report
- II. Call to Order for Business Meeting
- III. Declaration of a Quorum
- IV. Voting Items
- V. Final Voting and Closing of Polls
- VI. Preliminary Results of Voting
- VII. Questions and Answers
- VIII. Adjournment





The Polls Are Closed

- I. Chairman's Welcome and Report
- II. Call to Order for Business Meeting
- III. Declaration of a Quorum
- IV. Voting Items
- V. Final Voting and Closing of Polls
- VI. Preliminary Results of Voting
- VII. Questions and Answers
- VIII. Adjournment



- I. Chairman's Welcome and Report
- II. Call to Order for Business Meeting
- III. Declaration of a Quorum
- IV. Voting Items
- V. Final Voting and Closing of Polls
- VI. Preliminary Results of Voting
- VII. Questions and Answers
- VIII. Adjournment



- I. Chairman's Welcome and Report
- II. Call to Order for Business Meeting
- III. Declaration of a Quorum
- IV. Voting Items
- V. Final Voting and Closing of Polls
- VI. Preliminary Results of Voting
- VII. Questions and Answers
- VIII. Adjournment





Thank You!



Annual Meeting of Shareholders

April 23, 2009 Atlanta, Georgia